JP2018522888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522888A5 JP2018522888A5 JP2018501345A JP2018501345A JP2018522888A5 JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5 JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018501345 A JP2018501345 A JP 2018501345A JP 2018522888 A5 JP2018522888 A5 JP 2018522888A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated polypeptide
- seq
- nos
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 70
- 229920001184 polypeptide Polymers 0.000 claims 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims 69
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 24
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 13
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000030833 cell death Effects 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims 2
- 101710204410 Scaffold protein Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 claims 1
- 108010068032 caltractin Proteins 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193309P | 2015-07-16 | 2015-07-16 | |
| US62/193,309 | 2015-07-16 | ||
| PCT/US2016/042862 WO2017011837A2 (en) | 2015-07-16 | 2016-07-18 | Multivalent and multispecific dr5-binding fusion proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020196358A Division JP7244938B2 (ja) | 2015-07-16 | 2020-11-26 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522888A JP2018522888A (ja) | 2018-08-16 |
| JP2018522888A5 true JP2018522888A5 (OSRAM) | 2019-07-04 |
| JP6807606B2 JP6807606B2 (ja) | 2021-01-06 |
Family
ID=57757772
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501345A Active JP6807606B2 (ja) | 2015-07-16 | 2016-07-18 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| JP2020196358A Active JP7244938B2 (ja) | 2015-07-16 | 2020-11-26 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| JP2022191038A Pending JP2023022214A (ja) | 2015-07-16 | 2022-11-30 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| JP2025032594A Pending JP2025084923A (ja) | 2015-07-16 | 2025-03-03 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020196358A Active JP7244938B2 (ja) | 2015-07-16 | 2020-11-26 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| JP2022191038A Pending JP2023022214A (ja) | 2015-07-16 | 2022-11-30 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| JP2025032594A Pending JP2025084923A (ja) | 2015-07-16 | 2025-03-03 | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10308720B2 (OSRAM) |
| EP (2) | EP3798232A1 (OSRAM) |
| JP (4) | JP6807606B2 (OSRAM) |
| KR (2) | KR20250017305A (OSRAM) |
| CN (2) | CN114106178A (OSRAM) |
| AU (2) | AU2016291701B2 (OSRAM) |
| CA (1) | CA2991634A1 (OSRAM) |
| CY (1) | CY1123615T1 (OSRAM) |
| DK (1) | DK3322734T3 (OSRAM) |
| ES (1) | ES2833773T3 (OSRAM) |
| HR (1) | HRP20201785T1 (OSRAM) |
| HU (1) | HUE051896T2 (OSRAM) |
| IL (3) | IL292037A (OSRAM) |
| LT (1) | LT3322734T (OSRAM) |
| MX (2) | MX2018000523A (OSRAM) |
| NZ (1) | NZ777930A (OSRAM) |
| PL (1) | PL3322734T3 (OSRAM) |
| PT (1) | PT3322734T (OSRAM) |
| RS (1) | RS61062B1 (OSRAM) |
| RU (2) | RU2021111382A (OSRAM) |
| SG (1) | SG10201912410TA (OSRAM) |
| SI (1) | SI3322734T1 (OSRAM) |
| SM (1) | SMT202100066T1 (OSRAM) |
| WO (1) | WO2017011837A2 (OSRAM) |
| ZA (1) | ZA201800238B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| CN118852460A (zh) * | 2017-12-28 | 2024-10-29 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| IL323061A (en) | 2018-04-11 | 2025-10-01 | Inhibrx Biosciences Inc | Multispecific polypeptide constructs with forced CD3 binding and related methods and uses |
| WO2020047705A1 (zh) * | 2018-09-03 | 2020-03-12 | 安菲尼生命科技有限公司 | Dr5单域抗体及其用途 |
| GB201903767D0 (en) * | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
| AU2020358898B2 (en) * | 2019-10-01 | 2025-10-16 | Epsilogen Ltd | Hybrid antibody |
| JP7620780B2 (ja) * | 2020-06-30 | 2025-01-24 | ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| CN117098778A (zh) * | 2021-02-19 | 2023-11-21 | 印希比股份有限公司 | Dr5结合多肽的配制品 |
| WO2023196943A1 (en) * | 2022-04-08 | 2023-10-12 | Inhibrx, Inc. | Dr5 agonist and plk1 inhibitor or cdk inhibitor combination therapy |
| AU2023275703A1 (en) * | 2022-05-23 | 2024-11-21 | Inhibrx Biosciences, Inc. | Dr5 agonist and iap antagonist combination therapy |
| CN117285644A (zh) * | 2022-06-16 | 2023-12-26 | 清华大学 | 一种相变调节元件及其用途 |
| EP4594344A2 (en) | 2022-09-28 | 2025-08-06 | Valink Therapeutics Ltd | Multivalent proteins and screening methods |
| TW202515917A (zh) * | 2023-06-29 | 2025-04-16 | 美商奧迪希治療公司 | 抗trailr2抗原結合蛋白及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2098824A1 (en) | 1990-12-20 | 1992-06-21 | William D. Huse | Optimization of binding proteins |
| US20020147140A1 (en) | 2000-01-31 | 2002-10-10 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| KR20070010046A (ko) * | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| KR20070107687A (ko) | 2004-12-31 | 2007-11-07 | 제넨테크, 인크. | Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도 |
| KR20080003321A (ko) | 2005-02-24 | 2008-01-07 | 세미네스 인코퍼레이티드 | 생물학적 샘플을 분류하는 조성물 및 방법 |
| WO2007022416A2 (en) | 2005-08-18 | 2007-02-22 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against beta-amyloid peptide |
| BRPI0619463A2 (pt) | 2005-12-06 | 2013-01-08 | Domantis Ltd | ligando, uso do mesmo, mÉtodos para tratar cÂncer e para administrar um tratamento anti-vegf e tratamento anti-egfr a um indivÍduo, composiÇço, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodo para produzir um ligando, polipeptÍdeo de domÍnio variÁvel simples de imunoglobulina, e, antagonista de egfr |
| WO2007097923A2 (en) | 2006-02-20 | 2007-08-30 | Phylogica Limited | Method of constructing and screening libraries of peptide structures |
| JP2008133206A (ja) | 2006-11-28 | 2008-06-12 | Yokohama City Univ | 緑膿菌に対して感染防御能を誘導できる医薬組成物 |
| EA201000903A1 (ru) | 2007-11-30 | 2011-02-28 | Калобиос Фармасьютикалс, Инк. | Антитела к pcrv-антигену pseudomonas aeruginosa |
| DK2285408T3 (en) * | 2008-06-05 | 2019-02-04 | Ablynx Nv | AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES |
| WO2010030182A2 (en) | 2008-09-10 | 2010-03-18 | Bac Ip B.V. | Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases |
| EP2408475B1 (en) | 2009-03-18 | 2017-11-15 | Wake Forest University Health Sciences | Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
| WO2010115141A2 (en) | 2009-04-02 | 2010-10-07 | New York University | System and uses for generating databases of protein secondary structures involved in inter-chain protein interactions |
| CN101717775B (zh) * | 2009-11-13 | 2012-01-04 | 厦门大学 | 抗人死亡受体5的单链抗体基因 |
| US8962807B2 (en) | 2009-12-14 | 2015-02-24 | Ablynx N.V. | Single variable domain antibodies against OX40L, constructs and therapeutic use |
| US9120855B2 (en) * | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| US8623369B2 (en) | 2010-04-27 | 2014-01-07 | National Research Council Of Canada | Anti-ICAM-1 single domain antibody and uses thereof |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| WO2012055030A1 (en) | 2010-10-25 | 2012-05-03 | National Research Council Of Canada | Clostridium difficile-specific antibodies and uses thereof |
| BR112013016254A2 (pt) | 2010-12-23 | 2017-07-11 | Intercell Austria Ag | agentes oprf/i e seu uso em pacientes hospitalizados e outros |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| SMT202000091T1 (it) * | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| ES2749349T3 (es) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Proteínas de unión multiespecíficas y multivalentes y usos de las mismas |
| HK1204477A1 (en) | 2011-12-20 | 2015-11-20 | 阿达拉塔合伙有限公司 | Single domain antibodies as inhibitors of pcsk9 |
| JP6415987B2 (ja) | 2012-03-02 | 2018-10-31 | アブリンクス エン．ヴェー． | シュードモナス・エルギノーサのＰｃｒＶに結合する単一可変ドメイン抗体 |
| WO2013167883A1 (en) | 2012-05-07 | 2013-11-14 | The University Court Of The University Of Aberdeen | Single domain binding molecule |
| EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| EP2895510A2 (en) | 2012-09-13 | 2015-07-22 | Novartis AG | Single domain antibody with c-terminal modification |
| EP2917236A2 (en) | 2012-11-06 | 2015-09-16 | MedImmune, LLC | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| CN102924600B (zh) * | 2012-11-14 | 2013-10-30 | 河南大学 | 死亡受体5激动性多价抗体及其在制备抗肿瘤药物中的应用 |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| US9862777B2 (en) | 2013-05-28 | 2018-01-09 | Vib Vzw | Single domain antibodies against SOD1 and their use in medicine |
| CN105916975B (zh) * | 2014-01-10 | 2020-08-07 | 学校法人帝京平成大学 | 重组专性厌氧革兰氏阳性菌 |
-
2016
- 2016-07-18 HU HUE16825315A patent/HUE051896T2/hu unknown
- 2016-07-18 EP EP20189995.2A patent/EP3798232A1/en active Pending
- 2016-07-18 KR KR1020257002277A patent/KR20250017305A/ko active Pending
- 2016-07-18 IL IL292037A patent/IL292037A/en unknown
- 2016-07-18 SG SG10201912410TA patent/SG10201912410TA/en unknown
- 2016-07-18 RU RU2021111382A patent/RU2021111382A/ru unknown
- 2016-07-18 CN CN202111039963.9A patent/CN114106178A/zh active Pending
- 2016-07-18 SM SM20210066T patent/SMT202100066T1/it unknown
- 2016-07-18 ES ES16825315T patent/ES2833773T3/es active Active
- 2016-07-18 LT LTEP16825315.1T patent/LT3322734T/lt unknown
- 2016-07-18 SI SI201631005T patent/SI3322734T1/sl unknown
- 2016-07-18 HR HRP20201785TT patent/HRP20201785T1/hr unknown
- 2016-07-18 CA CA2991634A patent/CA2991634A1/en active Pending
- 2016-07-18 US US15/213,296 patent/US10308720B2/en active Active
- 2016-07-18 PL PL16825315T patent/PL3322734T3/pl unknown
- 2016-07-18 NZ NZ777930A patent/NZ777930A/en unknown
- 2016-07-18 MX MX2018000523A patent/MX2018000523A/es unknown
- 2016-07-18 DK DK16825315.1T patent/DK3322734T3/da active
- 2016-07-18 EP EP16825315.1A patent/EP3322734B1/en active Active
- 2016-07-18 IL IL307994A patent/IL307994A/en unknown
- 2016-07-18 KR KR1020187000975A patent/KR102760380B1/ko active Active
- 2016-07-18 CN CN201680041274.2A patent/CN107922491B/zh active Active
- 2016-07-18 RU RU2018102803A patent/RU2748620C2/ru active
- 2016-07-18 WO PCT/US2016/042862 patent/WO2017011837A2/en not_active Ceased
- 2016-07-18 JP JP2018501345A patent/JP6807606B2/ja active Active
- 2016-07-18 RS RS20201315A patent/RS61062B1/sr unknown
- 2016-07-18 AU AU2016291701A patent/AU2016291701B2/en active Active
- 2016-07-18 PT PT168253151T patent/PT3322734T/pt unknown
-
2018
- 2018-01-07 IL IL256772A patent/IL256772B/en unknown
- 2018-01-12 ZA ZA2018/00238A patent/ZA201800238B/en unknown
- 2018-01-12 MX MX2023002379A patent/MX2023002379A/es unknown
-
2019
- 2019-04-18 US US16/387,754 patent/US11117973B2/en active Active
-
2020
- 2020-11-16 CY CY20201101085T patent/CY1123615T1/el unknown
- 2020-11-26 JP JP2020196358A patent/JP7244938B2/ja active Active
-
2021
- 2021-08-05 US US17/394,900 patent/US11976126B2/en active Active
-
2022
- 2022-11-30 JP JP2022191038A patent/JP2023022214A/ja active Pending
- 2022-12-21 AU AU2022291498A patent/AU2022291498A1/en active Pending
-
2024
- 2024-04-04 US US18/626,699 patent/US20240376220A1/en active Pending
-
2025
- 2025-03-03 JP JP2025032594A patent/JP2025084923A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522888A5 (OSRAM) | ||
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2020508655A5 (OSRAM) | ||
| JP2019116474A5 (OSRAM) | ||
| JP2021503455A5 (OSRAM) | ||
| JP2020525032A5 (OSRAM) | ||
| JP2019527553A5 (OSRAM) | ||
| JP2017504578A5 (OSRAM) | ||
| JP2018523493A5 (OSRAM) | ||
| JP2019532619A5 (OSRAM) | ||
| JP2010502183A5 (OSRAM) | ||
| JP2018520993A5 (OSRAM) | ||
| JP2009225799A5 (OSRAM) | ||
| EP3625249A1 (en) | Method of preparing ph-dependent antibodies | |
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2012501670A5 (OSRAM) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2013506428A5 (OSRAM) | ||
| JP2018526981A5 (OSRAM) | ||
| JP2017149720A5 (OSRAM) | ||
| JP2012525829A5 (OSRAM) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2018137110A (ru) | Антитела против psma и их применение | |
| JP2020514277A5 (OSRAM) | ||
| JP2012530487A5 (OSRAM) |